P-136 Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
Juan Du(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Wei Cao(National and Kapodistrian University of Athens), Ying Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lihong Weng(CTI BioPharma (United Kingdom)), Jia Liu(Air Force Medical University), Wanting Qiang(Shanghai Changzheng Hospital), Zhongyuan Feng, Wenling Li(Tianjin University), Jin Liu(Central China Normal University), Qi Zhang(Innovacell Biotechnologie (Austria)), Lianjun Shen(Shanghai CASB Biotechnology (China)), Lina Jin(Shanghai Changzheng Hospital), Xiaoqiang Fan(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Pei Guo(Shanghai Changzheng Hospital), Haiyan He(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Yanchun Jia(Shanghai Changzheng Hospital), Jing Lu(Shanghai Changzheng Hospital)
Cited by 0
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754
The rapid self-reconstruction of Fe-modified Ni hydroxysulfide for efficient and stable large-current-density water/seawater oxidation
|Energy & Environmental Science|2022|305
Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway
|Cell Metabolism|2020|238